NCT05212610View on ClinicalTrials.gov

Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

PHASE4CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

March 7, 2025

Study Completion Date

March 7, 2025

Conditions

COVID-19Corona Virus Infection

Interventions

BIOLOGICAL

Pfizer-BioNTech mRNA COVID-19 vaccine

Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors

collaborator

The Wallace Foundation

OTHER

lead

University of Michigan

OTHER